Published in final edited form as:

Bioorg Med Chem. 2009 September 15; 17(18): 6560–6566. doi:10.1016/j.bmc.2009.08.003.

Synthesis and antimalarial activity of new chloroquine analogues carrying a multifunctional linear side chain

Daniel P. Iwaniuk¹, Eric D. Whetmore¹, Nicholas Rosa¹, Kekeli Ekoue-Kovi¹, John Alumasa¹, Angel C. de Dios^{1,3}, Paul D. Roepe^{1,2,3}, and Christian Wolf^{1,3}

¹Department of Chemistry, Georgetown University

²Department of Biochemistry and Cellular and Molecular Biology, Georgetown University

³Center for Infectious Diseases, Georgetown University

Abstract

We report the synthesis and *in vitro* antimalarial activity of several new 4-amino- and 4-alkoxy-7-chloroquinolines carrying a linear dibasic side chain. Many of these chloroquine analogues have submicromolar antimalarial activity versus HB3 (chloroquine sensitive) and Dd2 (chloroquine resistant strain of *P. falciparum*) and low resistance indices were obtained in most cases. Importantly, compounds **11–15** and **24** proved to be more potent against Dd2 than chloroquine. Branching of the side chain structure proved detrimental to the activity against the CQR strain.

Introduction

Malaria remains one of the world's most widespread and devastating infectious diseases and affects approximately 2.4 billion people living in malaria-endemic areas. Recent estimates calculate approximately 600 million annual clinical infections with *Plasmodium falciparum*, 80 million with *Plasmodium vivax* and more than 2 million casualties - malaria kills one child under the age of 5 years every 30 seconds.^{1–3} Among the protozoan parasites of the genus *Plasmodium* causing malaria in humans, *Plasmodium falciparum* is the most lethal species while *vivax* is less morbid but carries the problem of severe relapses. Inexpensive and stable antimalarial drugs such as the 7-chloro-4-aminoquinoline derivative chloroquine (CQ) have kept malaria in check in most regions for decades. However, the rising number of malarial deaths is due in part to increased resistance to CQ and other drugs in *P. falciparum*.

Since the discovery of the antimalarial potency of quinine and other cinchona alkaloids, a variety of agents exhibiting a 4-substituted quinoline pharmacophore has been introduced. In particular, chloroquine, quinine and amodiaquine have proved to be among the most effective antimalarial drugs.^{4–6} The exact molecular mechanism that describes how quinoline-based antimalarial drugs function is not yet precisely known. Aminoquinolines form a complex with ferriprotoporphyrin IX (FPIX), which is generated in the digestive vacuole (DV) of the intraerythrocytic malaria parasite as a result of proteolysis of host hemoglobin.^{7,8} Free FPIX

© 2009 Elsevier Ltd. All rights reserved

Address correspondence to: Christian Wolf, Georgetown University, 37th and "O" Streets, Washington, DC 20057. Phone: 202 687 3468, Fax: 202 687 6209, cw27@georgetown.edu..

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

is cytotoxic and it is sequestered in the form of hemozoin, a crystalline Fe-O41 dimer that is structurally identical to synthetic β -hematin.^{9,10} Hemozoin is also known as "malaria pigment" and appears as a dark spot in the DV of the parasite, the organelle in which hemoglobin digestion and hemozoin formation occur. Drug-FPIX interactions inhibit conversion of hematin to hemozoin and hence its detoxification via crystallization, and the accumulation of significant concentrations of toxic FPIX-aminoquinoline adducts is believed to be ultimately responsible for killing the parasite.^{11–15} It is widely accepted that the 4-aminoquinoline pharmacophore plays a crucial role in the complexation to FPIX resulting in inhibition of hemozoin formation and parasite growth,¹⁶ while the presence of a basic amino group in the side chain is generally considered essential for trapping high concentrations of the drug in the acidic DV of the parasite.¹⁷

Previous studies relating the structure of aminoquinoline antimalarial drugs to their function have focused on modifications of the side chain and of the quinoline ring. Various studies have revealed that structural changes of the 7-chloroquinoline ring in CQ reduces the antimalarial activity,^{18,19} whereas variation of the CQ side chain appears to be more promising. In a study by Krogstad *et al.*, 7-chloroquinolines with *N,N*-diethylaminoalkyl side chains exhibiting spacers consisting of two to twelve methylene units were found to be as effective as chloroquine against CQ sensitive (CQS) strains.²⁰ Importantly, the homologues with either short or very long linkers between the two amino functions showed remarkable activity against CQ resistant (CQR) strains. Analogues of chloroquine with branched and linear side chains containing two and three methylenes between the amino groups were also found to have both *in vitro* and *in vivo* antiparasitic activity similar to that of chloroquine in CQS strains of *P. falciparum*, and were more effective than chloroquine against CQR strains.^{21,22}

Results and discussion

Based on the above findings, we have begun to systematically modify the length and basicity of the CQ side chain.^{23–25} In particular, 4-amino-7-chloroquinolines with a linear side chain bearing two aliphatic tertiary amino functions proved to be highly potent antimalarials and were found equally effective against both CQS and CQR strains. In a previous report, we altered the α -portion of the side chain in a series of 4-aminoquinolines and obtained superior antiparasitic activities when the quinolyl nitrogen and the central amino group were kept in close proximity.²³ We have therefore prepared analogues **1–15** exhibiting a varied β -segment while the α -portion was kept constant at optimized length (Figure 1).

Our synthetic approach towards heme-targeted antimalarials generally involves inexpensive materials and high-yielding steps in most cases. Treatment of 4,7-dichloroquinoline with excess of 1,2-diaminoethane gave almost quantitative amounts of *N*-(7-chloro-4-quinolyl) diaminoethane, **16**, as described previously.²⁵ Primary amine **16** then served as the common starting material for the synthesis of β -segment varied amides **1–5**, secondary amines **6–10** and tertiary amines **11–15** (Scheme 1). For example, one-pot amidation of **16** with bromoacetyl chloride followed by peripheral substitution with excess of diethylamine gave **1** in 60% yield. Reduction with borane and subsequent reaction with sodium borohydride in glacial acetic acid then furnished the corresponding amines **6** and **11** in 78% and 37% yield, respectively. The aminoquinolines **2**, **7**, and **12** were available from previous studies.²³ For comparison, we prepared branched aminoquinoline **18** using our established nucleophilic substitution and reductive alkylation protocols.

The antimalarial activity of compounds **1–15** and **18** was measured versus a CQS (HB3) and a CQR (Dd2) strain using a standardized assay based on SYBR Green I intercalation.^{26–28} The IC₅₀ values were calculated from experiments carried out in triplicate and compared to CQ (Table 1). Several compounds within this series showed promising antimalarial activity against

both strains tested and a low resistance index (RI). The RI provides a quantitative measurement of the antiparasmodial activity against CQR strains relative to that against CQS strains and reveals promising drug discovery leads.

It is important to note that several of our aminoquinolines afford antimalarial activity versus HB3 similar to that of CQ and we were pleased to find that some compounds were significantly more potent against the resistant strain Dd2 than CQ. In general, the antiparasmodial activity of tertiary amines **11–15** proved superior over those obtained for the corresponding secondary amines **6–10** and the amides **1–5**. Notably, the amines **11–15** have IC₅₀'s between 19.9 and 53.0 nM for Dd2 (CQ IC₅₀=122 nM). The resistance index for CQ is about 15 whereas the majority of the heme-targeted antiparasmodials prepared for this study have RI's below 10. Quinolines **12** to **15** combine high antimalarial activity against HB3 with low RI values ranging from 1.1 to 7.1. These new CQ analogues thus show activity versus a CQS strain similar to that of CQ and, more importantly, they retain their potency against a CQR strain. Our stepwise variation of one chain at a time reveals that small changes in the spacer length can have dramatic effects on the activity versus the two strains tested. For example, a shortening or lengthening of the β -segment in the side chain in compound **12** by only one methylene group increases the RI from 1.1 to 7.1 and 10.5, respectively. But excellent resistance indices are again obtained when the β -chain length is further increased (see compounds **14** and **15**). The data also demonstrate that a linear side chain motif is superior over a branched structure. In analogy to linear amines **11–15**, compound **18** has high potency against HB3 but significantly lower activity against Dd2.

Based on these observations and previous work,²⁵ we then decided to prepare CQ analogues **19–24** in which the 4-quinolyl amino function is replaced by an ether linker (Figure 2). As shown in Scheme 2, the amide derivatives can be prepared in two steps from 4,7-dichloroquinoline and an amino alcohol in the presence of strong base followed by EDC-promoted coupling with 3-diethylaminopropionic acid. However, we found that **19** and **22** are not stable to typical amide reduction conditions and we therefore prepared the corresponding amines via mesylation of alcohols **25** and **26** and substitution with either *N,N*-diethyldiaminopropane or *N,N,N'*-triethyldiaminopropane.²⁵

The replacement of the 4-quinolyl amino moiety by an ether group is known to significantly reduce the basicity of the quinolyl nitrogen. Based on titration experiments previously performed in our laboratories,²⁵ the pK_a of the quinolyl *N* in 4-aminoquinolines is approximately 8.5 whereas 4-alkoxyquinolines have a pK_a of 4.5. In contrast to the 4-aminoquinolines **1–15**, ethers **19–24** can therefore be expected to have a free, nonprotonated quinoline ring in the acidic DV. Ethers **19** and **22** are essentially monoprotic bases under physiological conditions and thus less prone to effective bioaccumulation in the DV which explains their relatively low antiparasmodial activity (Table 2). The secondary and tertiary amines **20**, **21**, **23**, and **24** possess two basic groups in the side chain which favors migration into the acidic DV. These compounds therefore show enhanced antimalarial activity versus HB3 and Dd2. Comparison with the screening results obtained for the 4-aminoquinolines **6–15**, reveals that ethers **20**, **21**, **23**, and **24** exhibit lower antimalarial potency but improved RI's. In particular, tertiary amine **24** is a promising new antimalarial lead and more effective against Dd2 than CQ.

Conclusion

A series of new antiparasmodial 7-chloroquinolyl-derived amines and ethers have been synthesized and tested against CQR and CQS *P. falciparum*. Many of the CQ analogues prepared for this study showed submicromolar antimalarial activity versus HB3 and Dd2. The impressive activity against Dd2 combined with the low resistance indices values of **11–15** and

24 demonstrate that systematic variations of both the CQ side chain structure and basicity provide new leads that can overcome antimalarial drug resistance.

Experimental

Cell Culture and Antimalarial Activity Measurements

Drug activities were assessed and IC₅₀ were quantified essentially as described previously.^{26–28} The aminoquinolines were diluted using complete media under sterile conditions and plated in a 96 well plate format. Sorbitol synchronized cultures were utilized with >95% of the parasites at the ring stage. Cultures were diluted to give a working stock of 0.5% parasitemia and 2% hematocrit (final hematocrit 1% & 0.5% Parasitemia). The plates were incubated for 72 h at 37 °C. After 72 h, 50 µL of 10x SYBR green I dye was added to each well, and the plate was incubated for 1 h at 37 °C. Fluorescence was measured at 530 nm (490 nm excitation) using a spectra geminiEM plate reader. Data analysis was performed using Sigma plot 9.0 software after downloading data in Excel format. For each assay, each drug dilution was analyzed in triplicate, and the results from at least two separate assays were averaged in each case (S.D. < 10% in each case). All drugs were tested against one chloroquine sensitive, and one chloroquine resistant strain of *P. falciparum* (HB3 and Dd2, respectively).

Synthesis

All reagents and solvents used were commercially available and used without further purification. Flash chromatography was performed on Kieselgel 60, particle size 0.032–0.063 mm. NMR spectra were obtained on a 400 MHz (¹H-NMR) and 100 MHz (¹³C-NMR) Varian FT-NMR spectrometer using CDCl₃ as solvent. Electrospray mass spectra (ESI-MS) were collected on a Thermo Finnigan LCQ instrument. Samples were dissolved in acetonitrile/water (1:1 v/v) containing 1% acetic acid (1 mg/mL) for MS analysis. Based on NMR spectroscopic and HPLC chromatographic analyses, all compounds were at least of 98% purity.

Representative procedure for the synthesis of compounds 1–5

A mixture of **16** (0.500 g, 2.26 mmol) and *N,N*-diisopropylethylamine (0.91 mL, 5.29 mmol) in anhydrous DMF was stirred vigorously at room temperature under nitrogen atmosphere. Bromoacetyl chloride (0.24 mL, 2.88 mmol) was added dropwise to the mixture and allowed to stir for 1 hour. Diethylamine (2.35 mL, 22.62 mmol) was then added and the reaction was stirred at room temperature for 72 hours. The mixture was concentrated *in vacuo* and purified by flash chromatography (1.1:1.0:0.1 hexanes:ethanol:triethylamine). Extraction of a solution in dichloromethane with aqueous NaHCO₃ and NaOH solution, dried over MgSO₄ and concentrated *in vacuo* to give **1** as a yellow solid (0.453 g, 1.36 mmol, 60%).

N-(7-Chloro-4-quinolyl)-N-(2-diethylaminoethanoyl)-1,2-diaminoethane, 1—¹H-NMR (400 MHz, CDCl₃) δ = 0.98 (t, *J* = 7.1 Hz, 6H), 2.54 (q, *J* = 7.1 Hz, 4H), 3.08 (s, 2H), 3.39 (m, 2H), 3.74 (m, 2H), 6.28 (d, *J* = 5.4 Hz, 1H), 6.92 (bs, 1H), 7.38 (dd, *J* = 2.1, 8.9 Hz, 1H), 7.81 (d, *J* = 8.9 Hz, 1H), 7.93 (d, *J* = 2.1 Hz, 2H), 8.48 (d, *J* = 5.4 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ = 12.3, 38.5, 46.1, 48.2, 57.4, 98.0, 117.3, 122.1, 125.4, 128.4, 134.8, 149.1, 150.1, 151.9, 175.4; MS (ESI) *m/z* calcd for C₁₇H₂₃ClN₄O 334.2. Found (M + H)⁺: 335.2.

N-(7-Chloro-4-quinolyl)-N-(4-diethylaminobutanoyl)-1,2-diaminoethane, 3—Employing 0.700 g (3.17 mmol) of **16** and 0.48 mL 4-bromobutyl chloride (4.13 mmol) in the procedure described above gave 0.624 g (1.72 mmol, 54%) of **3** as a yellow solid. ¹H-NMR (400 MHz, CDCl₃) δ = 1.00 (t, *J* = 7.3 Hz, 6H), 1.76–1.82 (m, 2H), 2.41 (t, *J* = 6.6 Hz, 2H), 2.47–2.56 (m, 6H), 3.35 (m, 2H), 3.64 (m, 2H), 6.24 (d, *J* = 5.4 Hz, 1H), 7.11 (bs, 1H), 7.34 (dd, *J* = 2.1, 8.9 Hz, 1H), 7.88 (d, *J* = 8.9 Hz, 1H), 7.89 (s, 1H), 8.44 (d, *J* = 5.4 Hz, 1H), 8.86

(t, $J = 5.8$ Hz, 1H). ^{13}C -NMR (100 MHz, CDCl_3) $\delta = 10.9, 22.4, 35.4, 38.4, 46.5, 52.7, 97.8, 117.3, 122.6, 125.1, 125.5, 127.8, 134.8, 148.8, 150.3, 151.7, 176.2$; MS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{27}\text{ClN}_4\text{O}$ 362.2. Found ($\text{M} + \text{H}$) $^+$: 363.7.

N-(7-Chloro-4-quinolyl)-N-(5-diethylaminopentanoyl)-1,2-diaminoethane, 4—

Employing 0.700 g (3.17 mmol) of **16** and 0.55 mL 5-bromovaleryl chloride (4.11 mmol) in the procedure described above gave 0.800 g (2.12 mmol, 67%) of **4** as a yellow solid. ^1H -NMR (400 MHz, CDCl_3) δ 0.92 (t, $J = 7.1$ Hz, 6H), 1.38–1.46 (m, 2H), 1.61–1.69 (m, 2H), 2.29 (t, $J = 7.3$ Hz, 2H), 2.35 (t, $J = 7.1$ Hz, 2H), 2.41 (q, $J = 7.1$ Hz, 4H), 3.34 (m, 2H), 3.67 (m, 2H), 6.23 (d, $J = 5.4$ Hz, 1H), 7.09 (bs, 1H), 7.32 (dd, $J = 2.1, 8.7$ Hz, 1H), 7.83 (d, $J = 5.3$ Hz, 2H), 7.85 (s, 1H), 8.40 (d, $J = 5.4$ Hz, 1H). ^{13}C -NMR (100 MHz, CDCl_3) $\delta = 11.4, 23.8, 26.4, 36.2, 38.7, 46.2, 46.6, 52.4, 98.0, 117.2, 122.1, 125.4, 128.3, 134.8, 149.0, 150.1, 151.9, 176.3$; MS (ESI) m/z calcd for $\text{C}_{20}\text{H}_{29}\text{ClN}_4\text{O}$ 376.2. Found ($\text{M} + \text{H}$) $^+$: 377.3.

N-(7-Chloro-4-quinolyl)-N-(6-diethylaminohexanoyl)-1,2-diaminoethane, 5—

Employing 0.700 g (3.17 mmol) of **16** and 0.62 mL 6-bromohexanoyl chloride (4.14 mmol) in the procedure described above gave 0.642 g (1.65 mmol, 52%) of **5** as a yellow solid. ^1H -NMR (400 MHz, CDCl_3) δ 0.95 (t, $J = 7.1$ Hz, 6H), 1.21–1.29 (m, 2H), 1.35–1.42 (m, 2H), 1.62–1.70 (m, 2H), 2.25–2.29 (m, 4H), 2.44 (q, $J = 7.1$ Hz, 4H), 3.34 (m, 2H), 3.68 (m, 2H), 6.23 (d, $J = 5.4$ Hz, 1H), 7.07 (bs, 1H), 7.32 (dd, $J = 2.0, 9.0$ Hz, 1H), 7.76 (t, $J = 6.0$ Hz, 1H), 7.82 (d, $J = 2.0$ Hz, 1H), 7.84 (s, 1H), 8.39 (d, $J = 5.4$ Hz, 1H). ^{13}C -NMR (100 MHz, CDCl_3) $\delta = 11.4, 25.5, 26.7, 27.0, 36.4, 38.7, 46.1, 46.7, 52.5, 98.0, 117.3, 122.1, 125.4, 128.3, 134.8, 149.0, 150.1, 151.8, 176.3$; MS (ESI) m/z calcd for $\text{C}_{21}\text{H}_{31}\text{ClN}_4\text{O}$ 390.2. Found ($\text{M} + \text{H}$) $^+$: 391.3.

Representative procedure for the synthesis of compounds 6–10

A solution of **1** (0.300 g, 0.90 mmol) in 10 mL of THF was heated to reflux and borane-dimethyl sulfide complex (0.45 mL, 5.4 mmol) was added. After 2.5 hours, 6 M HCl (1.45 mL, 9.0 mmol) and 2 mL of water were added and the mixture was heated to reflux for 1.5 hours. The clear solution was cooled to room temperature, basified with saturated NaOH and extracted with a 1:1 mixture of CH_2Cl_2 and CHCl_3 . The combined organic layers were dried over anhydrous MgSO_4 and concentrated *in vacuo*. Purification by flash chromatography using EtOH:hexanes:Et₃N (1:1:0.1 v/v) as the mobile phase gave **6** (0.224 g, 0.70 mmol, 78% yield) as a brown oil.

N-(7-Chloro-4-quinolyl)-N-(2-diethylaminoethyl)-1,2-diaminoethane, 6— ^1H -NMR (400 MHz, CDCl_3) δ 1.01 (t, $J = 7.1$ Hz, 6H), 2.50–2.58 (m, 6H), 2.70 (t, $J = 5.8$ Hz, 2H), 3.02 (t, $J = 5.8$ Hz, 2H), 3.33 (m, 2H), 5.97 (bs, 1H), 6.38 (d, $J = 5.4$ Hz, 1H), 7.34 (dd, $J = 2.1, 8.9$ Hz, 1H), 7.73 (d, $J = 8.9$ Hz, 1H), 7.93 (d, $J = 2.1$ Hz, 1H), 8.51 (d, $J = 5.4$ Hz, 1H); ^{13}C -NMR (100 MHz, CDCl_3) $\delta = 11.7, 42.0, 46.8, 47.0, 47.4, 52.5, 99.1, 117.4, 121.4, 125.1, 128.6, 134.7, 149.1, 149.9, 152.0$; MS (ESI) m/z calcd for $\text{C}_{17}\text{H}_{25}\text{ClN}_4$ 320.2. Found ($\text{M} + \text{H}$) $^+$: 321.1.

N-(7-Chloro-4-quinolyl)-N-(4-diethylaminobutyl)-1,2-diaminoethane, 8—

Employing 0.300 g (0.83 mmol) of **3** in the procedure described above gave 0.101 g (0.29 mmol, 35%) of **8** as yellow oil. ^1H -NMR (400 MHz, CDCl_3) δ 1.01 (t, $J = 7.2$ Hz, 6H), 1.53–1.56 (m, 4H), 2.45 (m, 2H), 2.53 (q, $J = 7.2$ Hz, 4H), 2.68 (m, 2H), 3.03 (m, 2H), 3.34 (m, 2H), 6.10 (bs, 1H), 6.36 (d, $J = 5.4$ Hz, 1H), 7.34 (dd, $J = 2.1, 8.9$ Hz, 1H), 7.79 (d, $J = 8.9$ Hz, 1H), 7.92 (d, $J = 2.1$ Hz, 1H), 8.50 (d, $J = 5.4$ Hz, 1H); ^{13}C -NMR (100 MHz, CDCl_3) $\delta = 11.4, 24.8, 28.1, 41.8, 46.7, 47.3, 49.2, 52.7, 99.0, 117.5, 121.6, 125.2, 128.6, 134.8, 149.2, 149.9, 152.0$; MS (ESI) m/z calcd for $\text{C}_{19}\text{H}_{29}\text{ClN}_4$ 348.2. Found ($\text{M} + \text{H}$) $^+$: 349.2.

N-(7-Chloro-4-quinolyl)-N-(5-diethylaminopentyl)-1,2-diaminoethane, 9—

Employing 0.300 g (0.80 mmol) of **4** in the procedure described above gave 0.170 g (0.47 mmol, 59%) of **9** as a yellow oil. ¹H-NMR (400 MHz, CDCl₃) δ = 1.07 (t, *J* = 7.2 Hz, 6H), 1.37 (m, 2H), 1.52–1.57 (m, 4H), 2.48 (m, 2H), 2.61 (q, *J* = 7.2 Hz, 4H), 2.68 (t, *J* = 7.0 Hz, 2H), 3.04 (m, 2H), 3.34 (m, 2H), 5.99 (bs, 1H), 6.38 (d, *J* = 5.4 Hz, 1H), 7.35 (dd, *J* = 2.1, 8.9 Hz, 1H), 7.76 (d, *J* = 8.9 Hz, 1H), 7.93 (d, *J* = 2.1 Hz, 1H), 8.51 (d, *J* = 5.4 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ = 11.0, 25.2, 26.3, 29.8, 41.7, 46.8, 47.4, 48.9, 99.2, 121.5, 125.2, 128.7, 134.8, 149.2, 150.0, 152.1; MS (ESI) *m/z* calcd for C₂₀H₃₁ClN₄ 362.2. Found (M + H)⁺: 363.4.

N-(7-Chloro-4-quinolyl)-N-(6-diethylaminohexyl)-1,2-diaminoethane, 10—

Employing 0.300 g (0.77 mmol) of **5** in the procedure described above gave 0.147 g (0.39 mmol, 51%) of **10** as a yellow oil. ¹H-NMR (400 MHz, CDCl₃) δ = 1.01 (t, *J* = 7.2 Hz, 6H), 1.25–1.55 (m, 9H), 2.38 (m, 2H), 2.51 (q, *J* = 7.2 Hz, 4H), 2.64 (m, 2H), 3.02 (m, 2H), 3.30–3.4 (m, 2H), 5.94 (bs, 1H), 6.37 (d, *J* = 5.4 Hz, 1H), 7.34 (dd, *J* = 2.1, 8.9 Hz, 1H), 7.71 (d, *J* = 8.9 Hz, 1H), 7.93 (d, *J* = 2.1 Hz, 1H), 8.50 (d, *J* = 5.4 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ = 11.6, 27.0, 27.3, 27.6, 30.2, 41.9, 46.9, 47.2, 49.2, 52.9, 99.2, 117.4, 121.3, 125.2, 128.8, 134.8, 149.2, 149.9, 152.1; MS (ESI) *m/z* calcd for C₂₁H₃₃ClN₄ Found (M + H)⁺: 377.5.

Representative procedure for the synthesis of compounds 11–15

To a solution of **6** (0.070 g, 0.22 mmol) in 5 mL of glacial acetic acid, NaBH₄ (0.293 g, 7.7 mmol) was added at 0 °C and the reaction temperature was increased to 60 °C. After 48 hours, the reaction mixture was cooled, basified with saturated NaOH, extracted with CH₂Cl₂ and washed with brine. The combined organic layers were dried over anhydrous MgSO₄ and concentrated *in vacuo*. Purification by flash chromatography using CH₂Cl₂:hexanes (1:1 v/v) as the mobile phase gave **11** (0.029 g, 0.080 mmol, 37% yield) as a yellow oil.

N-(7-Chloro-4-quinolyl)-N'-ethyl-N'-(2-diethylaminoethyl)-1,2-diaminoethane, 11—

¹H-NMR (400 MHz, CDCl₃) δ = 0.99 (t, *J* = 7.1 Hz, 6H), 1.06 (t, *J* = 7.1 Hz, 3H), 2.53–2.64 (m, 10H), 2.83 (t, *J* = 5.5 Hz, 2H), 3.24 (m, 2H), 6.34 (d, *J* = 5.4 Hz, 1H), 6.36 (bs, 1H), 7.32 (dd, *J* = 2.1, 8.9 Hz, 1H), 7.77 (d, *J* = 8.9 Hz, 1H), 7.92 (d, *J* = 2.1 Hz, 1H), 8.50 (d, *J* = 5.4 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ = 11.3, 11.9, 40.0, 47.3, 47.5, 50.6, 50.8, 99.1, 117.6, 121.8, 124.8, 134.6, 149.2, 150.0, 152.1; MS (ESI) *m/z* calcd for C₁₉H₂₉ClN₄ 348.2. Found (M + H)⁺: 349.1.

N-(7-Chloro-4-quinolyl)-N'-ethyl-N'-(4-diethylaminobutyl)-1,2-diaminoethane, 13—

Employing 0.100 g (0.29 mmol) of **8** in the procedure described above gave 0.086 g (0.23 mmol, 80%) of **13** as a light yellow oil. ¹H-NMR (400 MHz, CDCl₃) δ = 0.99 (t, *J* = 7.1 Hz, 6H), 1.07 (t, *J* = 7.1 Hz, 3H), 1.46–1.48 (m, 4H), 2.39 (m, 2H), 2.43–2.48 (m, 4H), 2.52 (m, 2H), 2.59 (m, 2H), 2.81 (t, *J* = 5.6 Hz, 2H), 3.24 (m, 2H), 6.06 (bs, 1H), 6.35 (d, *J* = 5.3 Hz, 1H), 7.34 (dd, *J* = 2.0, 8.9 Hz, 1H), 7.64 (d, *J* = 8.9 Hz, 1H), 7.93 (d, *J* = 2.0 Hz, 1H), 8.51 (d, *J* = 5.3 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ = 11.6, 11.9, 25.0, 25.4, 39.7, 46.8, 46.9, 51.1, 52.8, 52.9, 99.3, 117.4, 121.0, 125.2, 128.7, 134.7, 149.1, 149.8, 152.1; MS (ESI) *m/z* calcd for C₂₁H₃₃ClN₄ 376.2. Found (M + H)⁺: 377.4.

N-(7-Chloro-4-quinolyl)-N'-ethyl-N'-(5-diethylaminopentyl)-1,2-diaminoethane, 14—

Employing 0.100 g (0.28 mmol) of **9** in the procedure described above gave 0.075 g (0.19 mmol, 70%) of **14** as a light yellow oil. ¹H-NMR (400 MHz, CDCl₃) δ = 0.98 (t, *J* = 7.1 Hz, 6H), 1.07 (t, *J* = 7.1 Hz, 3H), 1.29 (m, 2H), 1.42–1.54 (m, 4H), 2.33 (m, 2H), 2.45–2.51 (m, 6H), 2.60 (q, *J* = 7.1 Hz, 4H), 2.81 (t, *J* = 5.6 Hz, 2H), 3.24 (m, 2H), 6.07 (bs, 1H), 6.36 (d, *J* = 5.2 Hz, 1H), 7.34 (dd, *J* = 2.1, 8.9 Hz, 1H), 7.63 (d, *J* = 8.9 Hz, 1H), 7.93 (d, *J* = 2.1 Hz, 1H), 8.51 (d, *J* = 5.4 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ = 11.5, 12.0, 25.5, 27.0, 27.3, 39.7,

46.8, 46.9, 51.2, 52.8, 52.9, 99.3, 117.5, 121.1, 125.2, 128.8, 134.7, 149.2, 149.8, 152.2; MS (ESI) m/z calcd for $C_{22}H_{35}ClN_4$ 390.2. Found $(M + H)^+$: 391.3.

N-(7-Chloro-4-quinolyl)-N'-ethyl-N''-(6-diethylaminoethyl)-1,2-diaminoethane, 15—Employing 0.100 g (0.27 mmol) of **10** in the procedure described above gave 0.085 g (0.21 mmol, 79%) of **15** as a light yellow oil. 1H -NMR (400 MHz, $CDCl_3$) δ = 1.04 (t, J = 7.2 Hz, 6H), 1.07 (t, J = 7.1 Hz, 3H), 1.24–1.50 (m, 6H), 2.41 (m, 2H), 2.47–2.50 (m, 4H), 2.53–2.60 (m, 6H), 2.81 (t, J = 5.6 Hz, 2H), 3.24 (m, 2H), 6.12 (bs, 1H), 6.35 (d, J = 5.3 Hz, 1H), 7.34 (dd, J = 2.2, 8.9 Hz, 1H), 7.65 (d, J = 8.9 Hz, 1H), 7.93 (d, J = 2.2 Hz, 1H), 8.51 (d, J = 5.3 Hz, 1H); ^{13}C -NMR (100 MHz, $CDCl_3$) δ = 11.0, 12.0, 26.3, 27.2, 27.4, 27.5, 29.7, 39.7, 46.7, 46.8, 47.0, 51.2, 52.6, 52.7, 99.3, 117.5, 121.2, 125.2, 128.7, 134.7, 149.1, 152.2; MS (ESI) m/z calcd for $C_{23}H_{37}ClN_4$ 403.3. Found $(M + H)^+$: 404.2.

N-(7-Chloro-4-quinolyl)-tris(2-aminoethyl)amine, 17—A mixture of 4,7-dichloroquinoline (1.0 g, 5.0 mmol) and tris(2-aminoethyl)amine (8.0 mL, 53.5 mmol) was heated to 90 °C for 30 hours under nitrogen atmosphere in a closed vessel with good stirring. The reaction was quenched with 20 mL of concentrated NaOH and extracted between CH_2Cl_2 and brine. The combined organic layers were dried over $MgSO_4$ and concentrated *in vacuo* to give a yellow solid (1.47 g, 4.79 mmol, 95%). 1H -NMR (400 MHz, $CDCl_3$) δ = (bs, 4H), 2.61 (t, J = 6.0 Hz, 4H), 2.80–2.83 (m, 4H), 2.85 (m, 2H), 3.28–3.32 (m, 2H), 6.33 (d, J = 5.4 Hz, 1H), 6.62 (bs, 1H), 7.28 (dd, J = 2.1, 8.9 Hz, 1H), 7.89 (dd, J = 2.1 Hz, 1H), 7.93 (d, J = 8.9 Hz, 1H), 8.48 (d, J = 5.4 Hz, 1H); ^{13}C -NMR (100 MHz, $CDCl_3$) δ = 39.8, 40.8, 52.0, 56.6, 99.1, 117.6, 122.0, 125.0, 128.5, 134.7, 149.2, 150.2, 152.0; MS (ESI) m/z calcd for $C_{15}H_{22}ClN_5$ 307.2. Found $(M + H)^+$: 308.2.

N-(7-Chloro-4-quinolyl)-N',N''-tetraethyl-tris(2-aminoethyl)amine, 18—To a solution of **17** (0.462 g, 1.5 mmol) in 10 mL of glacial acetic acid, $NaBH_4$ (4.26 g, 112.7 mmol) was added at 5 °C and the reaction was stirred at room temperature for 24 hours and then heated to 60 °C for 8 hours. The cooled reaction mixture was basified with saturated NaOH, extracted with CH_2Cl_2 and washed with brine. The combined organic layers were dried over anhydrous $MgSO_4$ and concentrated *in vacuo* to give a yellow solid (0.315 g, 0.75 mmol, 50%). 1H -NMR (400 MHz, $CDCl_3$) δ = 0.97 (t, J = 7.2 Hz, 12H), 2.50–2.56 (m, 12H), 2.64–2.68 (m, 4H), 2.86 (m, 2H), 3.25 (m, 2H), 6.33 (d, J = 5.4 Hz, 1H), 6.51 (bs, 1H), 7.31 (dd, J = 2.1, 8.9 Hz, 1H), 7.84 (d, J = 8.9 Hz, 1H), 7.91 (d, J = 2.1 Hz, 1H), 8.49 (d, J = 5.4 Hz, 1H); ^{13}C -NMR (100 MHz, $CDCl_3$) δ = 11.1, 40.2, 47.2, 50.7, 51.5, 52.1, 99.1, 117.6, 122.2, 124.6, 128.5, 134.6, 149.2, 150.1, 152.1; MS (ESI) m/z calcd for $C_{23}H_{38}ClN_5$ 419.2. Found $(M + H)^+$: 420.3.

1-(7-Chloro-4-O-quinolyl)-N-(3-diethylaminopropanoyl)-2-aminoethane, 19—A mixture of *O*-(7-chloro-4-quinolyl)-2-aminoethanol, (0.300 g, 1.35 mmol), 3-diethylaminopropionic acid (0.270 g, 1.49 mmol), EDC (0.311 g, 1.62 mmol) and Et_3N (0.62 mL, 4.0 mmol) in 6 mL of anhydrous DMF and $CHCl_3$ (1:1 v/v) was stirred at room temperature for 20 hours. The reaction was concentrated *in vacuo*. Flash chromatography using $CH_2Cl_2:Et_3N$ (1:0.2 v/v) as the mobile phase gave 0.045 g (0.13 mmol, 16% yield) of white crystals. 1H -NMR (400 MHz, $CDCl_3$) δ = 0.97 (t, J = 7.1 Hz, 6H), 2.47–2.53 (m, 6H), 2.79 (t, J = 7.1 Hz, 2H), 3.57 (m, 2H), 4.49 (t, J = 5.1 Hz, 2H), 5.68 (bs, 1H), 6.39 (d, J = 5.3 Hz, 1H), 7.36 (dd, J = 2.1, 8.9 Hz, 1H), 7.69 (d, J = 8.9 Hz, 1H), 7.94 (d, J = 2.1 Hz, 1H), 8.53 (d, J = 5.3 Hz, 1H); ^{13}C -NMR (100 MHz, $CDCl_3$) δ = 11.7, 32.7, 43.1, 46.8, 48.2, 62.3, 98.9, 117.2, 125.5, 128.8, 135.0, 149.1, 149.5, 152.0, 173.8; MS (ESI) m/z calcd for $C_{18}H_{24}ClN_3O_2$ 349.2. Found $(M + H)^+$: 350.1.

1-(7-Chloro-4-O-quinolyl)-N-(3-diethylaminopropyl)-2-aminoethane, 20—To a solution of **25** (0.200 g, 0.90 mmol) and Et_3N (0.39 g, 2.7 mmol) in 4 mL of anhydrous THF

at room temperature was added dropwise methanesulfonyl chloride (0.21 mL, 2.7 mmol). The reaction proceeded with good stirring for 15 minutes and was then quenched with saturated NaHCO₃. The mixture was extracted with CH₂Cl₂, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was dissolved in anhydrous CH₃CN (3.0 mL) under inert atmosphere and Et₃N (0.62 g, 2.7 mmol) and *N,N*-diethyl diaminopropane (2.9 mL, 18.0 mmol) were added. The reaction mixture was stirred at 40 °C for 21 hours and saturated NaHCO₃ solution was added. The mixture was extracted with CH₂Cl₂, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The product was purified by flash column chromatography using CH₂Cl₂:Et₃N (1:0.2 v/v) as the mobile phase to give a light yellow oil (0.265 g, 0.79 mmol, 88% yield) ¹H-NMR (400 MHz, CDCl₃) δ = 1.01 (t, *J* = 7.2 Hz, 6H), 1.76 (m, 2H), 2.37 (t, *J* = 6.0 Hz, 2H), 2.50 (q, *J* = 7.2 Hz, 4H), 3.30 (t, *J* = 5.1 Hz, 2H), 3.48 (t, *J* = 6.0 Hz, 2H), 3.95 (t, *J* = 5.1 Hz, 2H), 6.85 (d, *J* = 5.1 Hz, 1H), 7.36 (dd, *J* = 2.2, 9.0 Hz, 1H), 7.96 (d, *J* = 2.2 Hz, 1H), 8.33 (d, *J* = 9.0 Hz, 1H), 8.61 (d, *J* = 5.1 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ = 10.0, 22.7, 45.7, 49.5, 58.4, 60.0, 109.7, 123.0, 125.8, 125.9, 128.7, 134.8, 150.8, 151.1, 155.5; MS (ESI) *m/z* calcd for C₁₈H₂₆ClN₃O 335.2. Found (M + H)⁺ 3 : 336.2.

1-(7-Chloro-4-O-quinolyl)-N'-ethyl-N'-(3-diethylaminopropyl)-2-aminoethane, 21

—To a solution of **25** (0.200 g, 0.90 mmol) and Et₃N (0.39 g, 2.7 mmol) in 4 mL of anhydrous THF at room temperature was added dropwise methanesulfonyl chloride (0.21 mL, 2.7 mmol). The reaction proceeded with good stirring for 15 minutes and was then quenched with saturated NaHCO₃. The mixture was extracted with CH₂Cl₂, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The residue was dissolved in anhydrous CH₃CN (3.0 mL) under inert atmosphere and Et₃N (0.62 g, 2.7 mmol) and *N,N,N'*-triethyl diaminopropane (0.340 g, 6.75 mmol) were added. The reaction mixture was stirred at 45 °C for 36 hours and saturated NaHCO₃ solution was added. The mixture was extracted with CH₂Cl₂, dried over anhydrous MgSO₄, and concentrated *in vacuo*. The product was purified by flash column chromatography using EtOH:hexanes:Et₃N (1:1.5:0.05 v/v) as the mobile phase to give a light yellow oil (0.035 g, 0.16 mmol, 18% yield) ¹H-NMR (400 MHz, CDCl₃) δ = 1.01 (t, *J* = 7.1 Hz, 6H), 1.10 (t, *J* = 7.1 Hz, 3H), 1.68 (m, 2H), 2.46 (t, *J* = 7.5 Hz, 2H), 2.52 (q, *J* = 7.1 Hz, 4H), 2.59 (t, *J* = 7.5 Hz, 2H), 2.68 (q, *J* = 7.1 Hz, 2H), 3.02 (t, *J* = 6.0 Hz, 2H), 4.25 (t, *J* = 6.0 Hz, 2H), 6.72 (d, *J* = 5.2 Hz, 1H), 7.42 (dd, *J* = 2.0, 8.9 Hz, 1H), 8.00 (d, *J* = 2.0 Hz, 1H), 8.12 (d, *J* = 8.9 Hz, 1H), 8.72 (d, *J* = 5.2 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ = 11.5, 12.0, 25.0, 46.8, 48.5, 50.9, 51.9, 52.6, 67.6, 101.0, 119.9, 123.5, 126.4, 127.9, 135.6, 149.7, 152.5, 161.5; MS (ESI) *m/z* calcd for C₂₀H₃₀ClN₃O 363.2. Found (M + H)⁺: 364.0.

1-(7-Chloro-4-O-quinolyl)-N-(3-diethylaminopropanoyl)-3-aminopropane, 22

—A mixture of *O*-(7-chloro-4-quinolyl)-3-aminopropanol (0.100 g, 0.45 mmol), 3-diethylaminopropionic acid (0.110 g, 0.6 mmol), EDC (0.110 g, 0.6 mmol) and Et₃N (0.19 mL, 1.35 mmol) in 4 mL of anhydrous DMF and CHCl₃ (1:1 v/v) was stirred at room temperature for 2 days. Saturated NaHCO₃ solution was added to the cooled reaction mixture, which was then extracted with CH₂Cl₂, dried over anhydrous MgSO₄, and concentrated *in vacuo*. Flash chromatography using EtOH:Et₃N (1:0.05 v/v) as the mobile phase afforded 0.100 g (0.44 mmol, 55 % yield) of yellow crystals. ¹H-NMR (400 MHz, CDCl₃) δ = 0.99 (t, *J* = 7.5 Hz, 6H), 2.20 (m, 2H), 2.40 (t, *J* = 6.5 Hz, 2H), 2.56 (q, *J* = 7.1 Hz, 4H), 2.70 (t, *J* = 6.1 Hz, 2H), 3.58 (q, *J* = 6.5 Hz, 4H), 4.24 (t, *J* = 6.1 Hz, 2H), 6.74 (d, *J* = 5.4 Hz, 1H), 7.23 (dd, *J* = 2.1, 9.0 Hz, 1H), 8.01 (bs, 1H), 8.20 (d, *J* = 9.0 Hz, 1H), 8.78 (d, *J* = 2.1 Hz, 1H), 8.90 (d, *J* = 5.4 Hz, 1H); ¹³C-NMR (100 MHz, CDCl₃) δ = 11.7, 29.3, 32.7, 35.8, 46.3, 49.1, 66.4, 101.1, 120.03, 123.6, 126.8, 128.2, 136.0, 150.0, 152.7, 161.7, 173.5; MS (ESI) *m/z* calcd for C₁₉H₂₆ClN₃O₂ 363.2. Found (M + H)⁺: 364.1.

1-(7-Chloro-4-O-quinolyl)-N-(3-diethylaminopropyl)-3-aminopropane, 23—To a solution of **26** (0.1 g, 0.4 mmol) and Et₃N (0.25 g, 2.3 mmol) in 20 mL of anhydrous THF at

room temperature was added dropwise methanesulfonyl chloride (0.11 g, 2.3 mmol). The reaction proceeded with good stirring for 10 minutes and was then quenched with saturated NaHCO_3 . The mixture was extracted with CH_2Cl_2 , dried over anhydrous MgSO_4 , and concentrated *in vacuo*. The residue was dissolved in anhydrous CH_3CN (3.0 mL) under inert atmosphere and *N,N*-diisopropylethylamine (0.5 g, 4.1 mmol) and *N,N*-diethyl diaminopropane (1.2 g, 15.2 mmol) were added. The reaction mixture was stirred at 40 °C for 48 hours and saturated NaHCO_3 solution was added. The mixture was extracted with CH_2Cl_2 , dried over anhydrous MgSO_4 , and concentrated *in vacuo*. The product was purified by flash column chromatography using CH_2Cl_2 :EtOH:Et₃N (5:1:0.005 v/v) as the mobile phase to give a light yellow oil (0.1 g, 0.32 mmol, 55% yield). ¹H-NMR (400 MHz, CDCl_3) δ (t, *J* = 6.6 Hz, 6H), 1.61–1.78 (m, 2H), 2.18 (m, 2H), 2.42–58 (m, 6H), 2.69 (t, *J* = 6.0 Hz, 2H), 2.90 (t, *J* = 6.0 Hz, 2H), 4.29 (t, *J* = 6.0 Hz, 2H), 6.72 (d, *J* = 5.1 Hz, 1H), 7.40 (dd, *J* = 2.1, 9.0 Hz, 1H), 8.01 (bs, 1H), 8.13 (d, *J* = 9.0 Hz, 1H), 8.72 (d, *J* = 5.1 Hz, 1H); ¹³C-NMR (100 MHz, CDCl_3) δ 27.03, 29.3, 46.5, 46.8, 48.9, 51.3, 66.8, 100.9, 119.8, 123.4, 126.4, 127.9, 135.6, 149.7, 152.5, 161.5; MS (ESI) *m/z* calcd for $\text{C}_{19}\text{H}_{28}\text{ClN}_3\text{O}$ 349.2. Found (*M* + *H*)⁺: 350.2.

1-(7-Chloro-4-O-quinolyl)-N'-ethyl-N'-(3-diethylaminopropyl)-3-aminopropane, 24—To a solution of **26** (0.1 g, 0.4 mmol) and Et₃N (0.25 g, 2.3 mmol) in 20 mL of anhydrous THF at room temperature was added dropwise methanesulfonyl chloride (0.11 g, 2.3 mmol). The reaction proceeded with good stirring for 10 minutes and was then quenched with saturated NaHCO_3 . The mixture was extracted with CH_2Cl_2 , dried over anhydrous MgSO_4 , and concentrated *in vacuo*. The residue was dissolved in anhydrous CH_3CN (3.0 mL) under inert atmosphere and *N,N*-diisopropylethylamine (0.5 g, 4.1 mmol) and *N,N,N'*triethyl diaminopropane (1.2 g, 14.3 mmol) were added. The reaction mixture was stirred at 40 °C for 48 hours and was quenched with saturated NaHCO_3 . The mixture was extracted with CH_2Cl_2 , dried over anhydrous MgSO_4 , and concentrated *in vacuo*. The product was purified by flash column chromatography using CH_2Cl_2 :EtOH:Et₃N (5:1:0.005 v/v) as the mobile phase to give a light yellow oil (0.03 g, 0.08 mmol, 40% yield). ¹H-NMR (400 MHz, CDCl_3) δ (t, *J* = 6.6 Hz, 6H), 1.60 (m, 2H), 2.00–2.18 (m, 2H), 2.40–2.60 (m, 6H), 2.64 (t, *J* = 6.0 Hz, 2H), 4.23 (t, *J* = 6.0 Hz, 2H), 6.73 (d, *J* = 5.1 Hz, 1H), 7.44 (dd, *J* = 2.1, 6.0 Hz, 1H), 8.01 (s, 1H), 8.13 (d, *J* = 6.0 Hz, 1H), 8.72 (d, *J* = 5.1 Hz, 1H); ¹³C-NMR (100 MHz, CDCl_3) δ = 11.6, 12.4, 27.03, 28.5, 29.3, 46.5, 46.8, 48.9, 51.3, 66.8, 100.9, 119.8, 123.4, 126.4, 127.9, 135.6, 149.7, 152.5, 161.5; MS (ESI) *m/z* calcd for $\text{C}_{21}\text{H}_{32}\text{ClN}_3\text{O}$ 377.2. Found (*M* + *H*)⁺: 378.2.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgment

We thank the National Institutes of Health (Grant RO1AI060792) for financial support. This work was in part supported by the National Science Foundation (REU CHE-0449829).

References

1. Mendis K, Sina BJ, Marchesini P, Carter R. Am. J. Trop. Med. Hyg 2001;64(Suppl 1):97–106. [PubMed: 11425182]
2. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. Nature 2005;434(7030):214–217. [PubMed: 15759000]
3. Greenwood BM, Fidock DA, Kyle DE, Kappe SHI, Alonso PL, Collins FH, Duffy PE. J. Clin. Invest 2008;118:1266–1276. [PubMed: 18382739]

4. De D, Byers LD, Krogstad DJ. *J. Heterocyclic Chem* 1997;34:315–320.
5. O'Neill PM, Bray PG, Hawley SR, Ward SA, Park BK. *Pharmacol. Ther* 1998;77:29–58. [PubMed: 9500158]
6. Dominguez JN. *Curr. Topics Med. Chem* 2002;2:1173–1185.
7. Zarchin S, Krugliak M, Ginsburg H. *Biochem. Pharmacol* 1986;35:2435. [PubMed: 3524576]
8. Sherman IW. *Bull. W. H. O* 1977;55:265. [PubMed: 338183]
9. Pagola S, Stephens PW, Bohle DS, Kosar AD, Madsen SK. *Nature* 2000;404:307. [PubMed: 10749217]
10. Solomonov I, Osipova M, Feldman Y, Baetz C, Kjaer K, Robinson IK, Webster GT, McNaughton D, Wood BR, Weissbuch I, Leiserowitz L. *J. Am. Chem. Soc* 2007;129:2615–2627. [PubMed: 17290993]
11. Ridley RG. *Nature* 2002;415:686–693. [PubMed: 11832957]
12. Leed A, DuBay K, Ursos LM, Sears D, de Dios AC, Roepe PD. *Biochemistry* 2002;41:10245–10255. [PubMed: 12162739]
13. Chong CR, Sullivan DJ Jr. *Biochem Pharmacol* 2003;66:2201–2212. [PubMed: 14609745]
14. de Dios AC, Casabianca LB, Kosar A, Roepe PD. *Inorg Chem* 2004;43:8078–8084. [PubMed: 15578847]
15. de Dios AC, Tycko R, Ursos LMB, Roepe PD. *J. Phys. Chem. A* 2003;107:5821–5825.
16. Cheruku SR, Maiti S, Dorn A, Scoreaux B, Bhattacharjee AK, Ellis WY, Vennerstrom JL. *J. Med. Chem* 2003;46:3166–3169. [PubMed: 12825955]
17. Egan TJ, Hunter R, Kaschula CH, Marques HM, Mispion A, Walden J. *J. Med. Chem* 2000;43:283–291. [PubMed: 10649984]
18. Egan TJ, Hunter R, Kaschula CH, Marques HM, Mispion A, Walden J. *J. Med. Chem* 2000;43:283–291. [PubMed: 10649984]
19. Kaschula CH, Egan TJ, Hunter R, Basilico N, Parapani S, Tarameli D, Pasini E, Monti D. *J. Med. Chem* 2002;45:3531–3539. [PubMed: 12139464]
20. De D, Krogstad FM, Cogswell FB, Krogstad DJ. *Am. J. Trop. Med. Hyg* 1996;55:579. [PubMed: 9025680]
21. Ridley RG, Hofheinz W, Matile H, Jaquet C, Dorn A, Masciardi R, Jolidon S, Richter WF, Guenzi A, Girometta M, Urwyler H, Huber W, Thaithong S, Peters W. *Antimicrob. Agents Chemother* 1996;40:1846. [PubMed: 8843292]
22. Stocks PA, Raynes KJ, Bray PG, Park BK, O'Neill PM, Ward SA. *J. Med. Chem* 2002;45:4975–4983. [PubMed: 12408708]
23. Yearick K, Ekoue-Kovi K, Iwaniuk DP, Natarajan JK, Alumasa J, de Dios AC, Roepe PD, Wolf C. *J. Med. Chem* 2008;51:1995–1998. [PubMed: 18345611]
24. Ekoue-Kovi K, Yearick K, Iwaniuk DP, Natarajan JK, Alumasa J, de Dios AC, Roepe PD, Wolf C. *Bioorg. Med. Chem* 2009;17:270–283. [PubMed: 19041248]
25. Natarajan JK, Alumasa J, Yearick K, Ekoue-Kovi KA, Casabianca LB, de Dios A, Wolf C, Roepe PD. *J. Med. Chem* 2008;51:3466–3479. [PubMed: 18512900]
26. Bennett TN, Paguio M, Gligorijevic B, Seudieu C, Kosar AD, Davidson E, Roepe PD. *Antimicrob. Agents Chemother* 2004;48:1807–1810. [PubMed: 15105139]
27. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. *Antimicrob. Agents Chemother* 2004;48:1803–1806. [PubMed: 15105138]
28. Johnson JD, Denuel RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC. *Antimicrob. Agents Chemother* 2007;51:1926–1933. [PubMed: 17371812]

Figure 1.
Structures of 4-amino-7-chloroquinolines **1–15** carrying a linear side chain.

Scheme 1.

Synthesis of CQ-derived antimalarials carrying a linear side chain and of branched 4-aminoquinoline **18**.

Figure 2.
Structures of CQ 4O analogues **19–24**.

Scheme 2.
Synthesis of 4-alkoxy-derived 7-chloroquinolines **19–24**.

Table 1
Antiplasmodial activities of CQ analogues **1–15**.

Compound	Strain/IC ₅₀ (nM)		RI ^I
	HB3	Dd2	
CQ	8.4	122	14.6
1	715	3362	4.7
2	32	760	24.1
3	225	1187	5.3
4	228	1189	5.2
5	287	2704	9.4
6	10.8	1569	145
7	29.2	129	4.4
8	30.7	1274	41.5
9	28.9	459	15.9
10	68.9	231	3.4
11	5.0	53.0	10.5
12	27.3	31.2	1.1
13	5.1	36.2	7.1
14	8.9	38.7	4.3
15	5.0	19.9	4.0
18	7.0	151	21.5

IC₅₀'s are averages of two separate runs each conducted in triplicate.

^IThe resistance index (RI) is the ratio of the IC₅₀ for the resistant versus the sensitive strain (Dd2/HB3).

Table 2
Antiplasmodial activities of CQ analogues **19–24**.

Compound	IC ₅₀ (nM)		RI ^I
	HB3	Dd2	
CQ	9.8	138	14.1
19	1706	1456	0.9
20	94.6	214	2.3
21	321	409	1.3
22	2315	752	0.3
23	19.7	240	12.2
24	77.5	108	1.4

IC₅₀'s are averages of two separate runs each conducted in triplicate.

^IThe resistance index (RI) is the ratio of the IC₅₀ for the resistant versus the sensitive strain (Dd2/HB3).